Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

Dissection of T-cell Antigen Specificity in Human Melanoma

(2012) R. S. Andersen et al.   CANCER RESEARCH

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

(2011) S. Solito et al.   BLOOD

An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses

(2011) F. O. Pettersen et al.   JOURNAL OF VIROLOGY

Dendritic cell-based vaccine in advanced melanoma

(2011) Laura Ridolfi et al.   MELANOMA RESEARCH

Chemoimmunotherapy

(2010) Leisha A. Emens   CANCER JOURNAL

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

(2010) Isabel Poschke et al.   CANCER RESEARCH

Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

(2010) Laura Ridolfi et al.   Clinical & Developmental Immunology

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

(2010) J. F. M. Jacobs et al.   CLINICAL CANCER RESEARCH

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

(2010) Redas Trepiakas et al.   CYTOTHERAPY

Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma

(2010) Steven E. Finkelstein et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy

(2010) Thomas F. Gajewski   Pigment Cell & Melanoma Research

Chemotherapy and biologic therapies for melanoma: do they work?

(2009) Lucia B. Jilaveanu et al.   CLINICS IN DERMATOLOGY

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells

(2009) Mercedes N. López et al.   JOURNAL OF CLINICAL ONCOLOGY

COX-2 expression in malignant melanoma: a novel prognostic marker?

(2009) Maria R. Becker et al.   MELANOMA RESEARCH

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers

(2009) Sine Reker Hadrup et al.   NATURE METHODS

CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells

(2008) M. Kleinewietfeld et al.   BLOOD

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

(2008) Lotte Engell-Noerregaard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulatory T cells and treatment of cancer

(2008) Tyler J Curiel   CURRENT OPINION IN IMMUNOLOGY

Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma

(2008) Annika Berntsen et al.   JOURNAL OF IMMUNOTHERAPY